Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUS-RFA Plus Neoadjuvant Chemotherapy in Pancreatic Cancer
NCT04990609Phase 2Recruiting
- Sponsor
- UTHealth Houston
- Start
- Aug 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in pancreatic ductal adenocarcinoma (PDAC), sponsored by UTHealth Houston. Primary endpoint: Number of participants who are able to complete neoadjuvant chemotherapy plus EUS-RFA and later undergo surgical tumor resection. Started Aug 2021; status: recruiting.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04990609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990609.